OS Therapies Incorporated
$1.38
0%
2026-04-21 08:41:01
ostherapies.com
ASE: OSTX
Explore OS Therapies Incorporated stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$58.43 M
Current Price
$1.38
52W High / Low
$2.57 / $1.15
Stock P/E
—
Book Value
$-0.16
Dividend Yield
—
ROCE
582.87%
ROE
614.26%
Face Value
—
EPS
$-0.98
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
—
Debt / Equity
—
Current Ratio
0.03
Quick Ratio
0.03
Forward P/E
-4.59
Price / Sales
—
Enterprise Value
$52.19 M
EV / EBITDA
-1.84
EV / Revenue
—
Rating
Strong Buy
Target Price
$10.89
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Jaguar Health, Inc. | $0.41 | — | $5.34 M | — | -91.43% | -628.65% | $15.48 / $0.31 | $0.85 |
| 2. | Precision BioSciences, Inc. | $7.58 | — | $187.43 M | — | -35.84% | -62.71% | $8.82 / $3.53 | $3.83 |
| 3. | Abeona Therapeutics Inc. | $5.48 | 4.39 | $312.63 M | — | -47.08% | 70.05% | $7.54 / $4 | $2.89 |
| 4. | Solid Biosciences Inc. | $8.49 | — | $835.34 M | — | -90.02% | -1.1% | $8.87 / $2.41 | $2.28 |
| 5. | Eupraxia Pharmaceuticals Inc. | $7.2 | — | $599.04 M | — | -47.73% | -68.76% | $12.86 / $4.38 | $1.01 |
| 6. | Aspire Biopharma Holdings, Inc. | $0.26 | — | $1.36 M | — | 308.11% | 618.48% | $35 / $0.22 | $-1.8 |
| 7. | PharmaCyte Biotech, Inc. | $0.76 | — | $7.82 M | — | -8.38% | -8.24% | $1.51 / $0.63 | $3.59 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -11.99 M | -6.88 M | -4.84 M | -5 M | -2.97 M | — |
| Net Profit | -13.46 M | -6.88 M | -4.54 M | -3.88 M | -2.99 M | — |
| EPS in Rs | -0.33 | -0.17 | -0.11 | -0.1 | -0.07 | -0.18 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -28.71 M | -6.81 M | -4.34 M | -4.45 M |
| Net Profit | -28.75 M | -8.88 M | -7.79 M | -6.25 M |
| EPS in Rs | -0.71 | -0.22 | -0.19 | -0.15 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 6.84 M | 5.54 M | 0.8 M | 0.51 M |
| Total Liabilities | 12.94 M | 8.81 M | 24.81 M | 18.07 M |
| Equity | -6.1 M | -3.27 M | -24.02 M | -17.56 M |
| Current Assets | 0.33 M | 5.53 M | 0.79 M | 0.5 M |
| Current Liabilities | 11.76 M | 4.63 M | 24.71 M | 6.15 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -14.24 M | -7.28 M | -3.01 M | -3.79 M |
| Investing CF | -0.47 M | 0 M | 0 M | 0.23 M |
| Financing CF | 9.44 M | 12.78 M | 2.87 M | 3.65 M |
| Free CF | -14.7 M | -7.28 M | -3.01 M | -3.79 M |
| Capex | -0.47 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -14.01% | -24.57% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.